| __timestamp | Celldex Therapeutics, Inc. | Travere Therapeutics, Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 20622000 | 59644696 |
| Thursday, January 1, 2015 | 33837000 | 79541000 |
| Friday, January 1, 2016 | 35979000 | 98015000 |
| Sunday, January 1, 2017 | 25003000 | 103958000 |
| Monday, January 1, 2018 | 19269000 | 103654000 |
| Tuesday, January 1, 2019 | 15426000 | 128951000 |
| Wednesday, January 1, 2020 | 14456000 | 135799000 |
| Friday, January 1, 2021 | 20488000 | 149883000 |
| Saturday, January 1, 2022 | 27195000 | 220206000 |
| Sunday, January 1, 2023 | 30914000 | 265542000 |
In pursuit of knowledge
In the competitive world of biotechnology, managing operational expenses is crucial for success. This analysis compares the Selling, General, and Administrative (SG&A) expenses of Travere Therapeutics, Inc. and Celldex Therapeutics, Inc. over the past decade. From 2014 to 2023, Travere consistently outspent Celldex, with SG&A expenses peaking at $266 million in 2023, a staggering 330% increase from 2014. In contrast, Celldex's expenses grew by 50% over the same period, reaching $31 million in 2023. This disparity highlights Travere's aggressive investment in administrative functions, possibly reflecting a strategy to scale operations rapidly. Meanwhile, Celldex's more conservative spending may indicate a focus on lean operations. Understanding these trends provides valuable insights into each company's strategic priorities and operational efficiency. As the biotech landscape evolves, monitoring SG&A efficiency will remain a key indicator of financial health and strategic direction.
Operational Costs Compared: SG&A Analysis of Merck & Co., Inc. and Celldex Therapeutics, Inc.
Breaking Down SG&A Expenses: Gilead Sciences, Inc. vs Travere Therapeutics, Inc.
SG&A Efficiency Analysis: Comparing Summit Therapeutics Inc. and Travere Therapeutics, Inc.
SG&A Efficiency Analysis: Comparing Jazz Pharmaceuticals plc and Celldex Therapeutics, Inc.
Blueprint Medicines Corporation and Travere Therapeutics, Inc.: SG&A Spending Patterns Compared
SG&A Efficiency Analysis: Comparing Corcept Therapeutics Incorporated and Travere Therapeutics, Inc.
Cost Management Insights: SG&A Expenses for Ionis Pharmaceuticals, Inc. and Travere Therapeutics, Inc.
Selling, General, and Administrative Costs: Verona Pharma plc vs Travere Therapeutics, Inc.
Arrowhead Pharmaceuticals, Inc. vs Celldex Therapeutics, Inc.: SG&A Expense Trends
SG&A Efficiency Analysis: Comparing Mesoblast Limited and Travere Therapeutics, Inc.
Breaking Down SG&A Expenses: MannKind Corporation vs Travere Therapeutics, Inc.
SG&A Efficiency Analysis: Comparing Amphastar Pharmaceuticals, Inc. and Travere Therapeutics, Inc.